This work is to show which is more relevant to cause local failures (LFs) due to patient setup uncertainty between the planning target volume (PTV) underdosage and the potential target underdosage subject to patient setup uncertainties in head and neck (H&N) cancer treated with volumetric-modulated arc therapy (VMAT). Thirteen LFs in 10 H&N patients treated by VMAT were analyzed. Measures have been taken to minimize the chances of insufficient target delineation for these patients and the patients were clinically determined to have LF based on the PET/CT scan results by an experienced radiologist and then reviewed by a second experienced radiation oncologist.
| INTRODUCTION
Volumetric-modulated arc therapy (VMAT) is a novel form of intensity-modulated radiotherapy (IMRT) that can deliver complex, 3-dimensional dose distributions by using single or multiple arcs.
Compared with conventional static-field IMRT (hereafter termed IMRT), VMAT has the advantages of improved dose distributions, faster treatment delivery, and decreased monitor unit requirements. 1 Therefore, VMAT has been rapidly adopted as the preferred treatment technique for head and neck (H&N)
cancers. 2 Despite improved technologies in radiotherapy for H&N cancer, local failure (LF) remains the most important cause of patient morbidity and mortality. [3] [4] [5] [6] LF causes significant morbidity and often leads to death. Many factors are associated with LF after radiotherapy. In addition to biological factors inherent in the disease, technical aspects of radiotherapy may play a role in LF. To minimize severe complications such as brainstem necrosis, xerostomia, and dysphagia, radiation oncologists often reduce target margins, compromise the target coverage, or both, to avoid critical structures, resulting in a region of low dose, which in turn may cause LF. 4 Highly conformal treatment techniques such as IMRT and VMAT are capable of generating sharp dose gradients between tumors and nearby critical structures. However, uncertainties introduced by variations in patient setup (hereafter termed patient-setup uncertainties) and organ motion may lead to target underdosage, thus contributing to LF. 7 In planning for external beam therapy, setup uncertainties and organ motion are addressed by uniform geometric expansion of the clinical target volume (CTV) to form the planning target volume (PTV). 8 In our clinics, the PTV coverage is evaluated to assess the probability of LF due to patient setup uncertainties. 4, 9 This approach assumes the static dose cloud approximation, i.e., the approximation that the dose cloud is static relative to the room-coordinate system. 10 During the past decade, researchers have extensively studied the sensitivity of IMRT plans to uncertainties and organ motion in H&N cancer radiotherapy. 7, [11] [12] [13] [14] [15] [16] [17] However, few studies have investigated the sensitivity of VMAT plans to these uncertainties. 18 More importantly, almost all the reported studies 7, [11] [12] [13] [14] [15] [16] [17] are computer-based dosimetric investigations. To our knowledge, no studies have examined the association of LF observed in the clinic with VMAT plan robustness. Therefore, we evaluated data of 10 patients with H&N cancer presenting with a total of 13 LFs after being treated with VMAT in order to determine whether potential target underdosage subject to patient setup uncertainties may be a more relevant factor in predicting LF than the conventional PTV method.
| METHODS AND MATERIALS

2.A | Patient data and treatment planning
The scope of this work is limited to show which is more relevant to cause the LF due to patient setup uncertainty between the compromised PTV coverage and the potential target underdosage subject to patient setup uncertainties. Other complicated technical aspects and biological aspects including surgical seeding are not considered in this exploratory study.
In total 396 patients with H&N cancer were treated using VMAT Table 1 . The subsites of the tumors were oral cavity/ oropharynx (seven patients), nasopharynx (two patients), and supraglottic larynx (one patient). Tumors were classified into two classes: patients with T > 2 or N ≥ 2 were considered to be locally advanced (seven patients), otherwise they were considered as early stage (three patients). None of the patients had distant metastatic disease at presentation. Nine patients had histologically verified squamous cell carcinoma (SCC) and 1 patient had adenocarcinoma. All these patients had follow-up with PET/CT in at least 3 months after radiotherapy. Different from the planning CT simulation, the PET/CT scans are for the purpose of diagnosis and thus patients do not have any immobilization during the PET/CT. The patients were clinically determined to have LF based on the PET/CT scan results by an experienced radiologist and then reviewed by a second experienced radiation oncologist. 6 Each patient was treated using VMAT with 2 or 3 arcs. Two dose levels were prescribed and administered using a simultaneous integrated boost technique. The target region, which received a higher prescribed dose, was referred to as CTV High and the region that received a lower prescribed dose was referred to as CTV Low .
CTVs were delineated by a physician, with CTV High defined as the volume with gross disease or high risk microscopic disease (gross LIU ET AL. PTVs were cropped at least 3 mm from the skin if needed. The prescription doses and fractionation scheme varied (Table 1 ).
Doses to critical normal structures were constrained to meet acceptable tolerance dose values whenever possible as defined in the departmental H&N cancer treatment protocol (Table S1 ). All VMAT plans were generated by experienced dosimetrists or physicists using the treatment planning software Eclipse TM (Varian Medical Systems, Palo Alto, CA, USA) and were approved by the treating physician. A second review by a radiation oncologist was performed to verify that all plans met departmental criteria (Table S1 ).
2.B | Underdosed volume because of cold spots in
the PTVs in the nominal dose distribution (standard method to assess cold spots)
In photon radiation therapy, the dose distributions of PTVs are usually used to evaluate the impact of patient setup uncertainties. Two dose-volume histogram (DVH) indices were used to assess the PTV coverage: D 95% , the dose covering 95% of the PTV and V 95%, the subvolume of the PTV receiving 95% of the prescription dose.
Cold spots within the PTVs are possible sources of LF. The underdosed volume in the nominal dose distribution (UVN) due to the cold spots within the PTVs was generated by subtracting the volume that received prescription doses (V 100% ) from the PTVs:
2.C | Modelling of patient setup uncertainty and resultant underdosed volume (using robustness analysis to assess the potential cold spots)
A coldest setup deviation dose distribution was computed as fol- it is the PTV margin size used for these patients.
The coldest dose distribution subject to uncertainty was then imported to Eclipse TM and overlaid on the planning CT. The underdosed volume in the coldest dose distribution (UVC) was generated by 
2.D | Association of underdosed volumes with LF
All patients had PET/CT scans performed at least 3 months after radiotherapy. Each patient had LF within and around CTVs (both CTV High and CTV Low ), and three patients (patient # 4, 6 and 7, Table 2 ) had a second LF after salvage radiotherapy (total of 13 instances of LF). Failures were categorized as in-field, marginal, or out-of-field if > 95%, 20%-95%, or < 20% of the LF was within the 95% prescription iso-dose lines. 3 To facilitate spatial association, the PET/CT scan was registered to the planning CT using landmark-based rigid registration in Eclipse TM . 19 The registration uncertainty study was not performed and will be the research topic of the future study. However, the image registration was reviewed and approved by the treating physician.
The UVN (standard method) and UVC (robustness method) were then examined for spatial association with LF. If there was overlap of at least 0.5 cm 3 between the underdosed volume and the region of LF, the variable indicating association between the underdosed volumes and LF was set to be TRUE; otherwise it was set to be FALSE ( Table 3 ). The value of 0.5 cm 3 is chosen to have enough voxels to minimize the possible random errors. The association was further reviewed and approved by an experienced radiation oncologist.
2.E | Visualization of dose variation in the PTVs
The patient setup uncertainties may not only perturb the dose at the edge of PTVs, but also perturb the dose far from the edge of PTVs. To visualize the dose variation of VMAT plans in the PTVs in the face of patient setup uncertainties, we used the root-meansquare dose deviation (RMSD) robustness quantification technique proposed by Liu et al. [20] [21] [22] A similar concept of error-bar volume histogram was proposed by Albertini et al. 23 The RMSD of voxels was calculated as the square root of the sum square of the differences between the dose calculated under the uncertainty scenarios and the nominal scenario and the mean dose of those seven doses. The calculated RMSD dose file was imported back to Eclipse TM and visualized.
2.F | Statistical analyses
The null hypothesis was that the underdosed volume was independent of LF. Therefore, the binomial distribution with a probability of 0.5 was used to calculate the p value for the statistical significance of the association between the underdosed volume and LF. We further tested the relationship between the aforementioned association and tumor histology, location, stage, CTV High volume, and treatment modality by using the Fisher's exact test of independence. The 2 9 2 exact contingency table was used. 3 | RESULTS Table 2 . Of these 13 LFs, nine were in-field, three were marginal, and one was out-of-field LFs ( Table 2 ).
The D 95% and V 95% of PTV High and PTV Low in the nominal dose distribution are listed in Table 2 . Although the DVH indices for most patients suggested sufficient PTV coverage (≥ 99%), 24 (Table S2) .
To show dose variation in the PTVs, the RMSD distributions in three planes calculated from the perturbed doses corresponding to different scenarios of patient-setup uncertainty are shown in Fig. 3 .
Patient setup variation appeared to perturb the VMAT dose distribution in the middle of PTVs. One of the major causes for LFs is the suboptimal target delineation. 4, 9 The scope of this work is limited to show which is more relevant to cause the LF due to patient setup uncertainty between the compromised PTV coverage and the potential target underdosage subject to patient setup uncertainties. In this study all the targets were contoured by an experienced radiation oncologist and then reviewed by an independent experienced radiation oncologist.
| DISCUSSION
And an experienced radiation oncologist carefully reviewed all the patients with LF and chose patients, who were least likely to have insufficient target delineation. That is also the reason why none of the patients included in this study had the radiation target volumes cropped due to the protection of the nearby organs at risks. Some
PTVs were cropped at least 3 mm from the skin if needed due to the imperfection in the dose calculation of our treatment planning system. Fortunately, none of the LFs of the patients included in this study took place in these cropped volumes.
D 95% and V 95% of PTVs are parameters that are routinely used to evaluate adequacy of target dose coverage. The tumor control probability can be calculated based on various models by using PTV coverage. 25 Interestingly, six patients (Table 2) | 81 association between LF and UVN was not (P = 0.99) ( Table 3 ). This finding suggests that compared to the compromised PTV coverage due to patient setup uncertainty (an important LF indicator), the potential target underdosage subject to patient setup uncertainties is more relevant at least for the H&N cancer patients treated by VMAT included in this study.
Our study showed that most LFs occur within PTV High proposed using robust probabilistic planning to replace the concept of PTV in photon therapy. [26] [27] [28] [29] The plan robustness quantification tools developed for this study could help design knowledge-based anisotropic margins in our clinical practice. In addition, the knowledge acquired from this study might aid in further development of stringent image-guided radiotherapy and immobilization devices, as well as optimal motion management strategies for using VMAT to treat patients with H&N cancer.
Our study had limitations, including a small sample size. We did use the analysis of the Fisher's exact test of independence to check the dependence of the conclusions on tumor location, stage, volume, and treatment modality. The P-values are included in the Table S2 .
Based on this small patient population, it seems that the conclusion is independent of tumor location, stage, volume, and treatment modality.
However, a larger patient population is warranted to verify the clinical relevance of our brute force method, which will be included in our future study. Our patient cohort was also limited in disease subsites.
All of the patients had the disease below the eye level. Fried et al., 4 reported that in case of sinonasal malignancies, with the disease located at or above the eye level, target coverage was often compromised to protect the critical normal tissue adjacent to the orbit and base of skull, thus increasing the risk of LF in this area. Sinonasal cancer is an uncommon malignancy and we did not have any LFs in the recent past using VMAT that could be included for this study.
In summary, our work alerts radiotherapy practitioners not to rely solely on the standard method for assessment of VMAT PTV coverage to assess target control. The plan robustness analysis appears to be a significantly more important factor associated with LF than the conventional PTV underdosage measures for patients with H&N cancer treated with VMAT. A larger patient population study with a control group would be helpful for further investigation. 
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